sembragiline
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00622752)
Timeline
Indications
Mechanism of action
- Monoamine oxidase BINHIBITOR
MAOB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H]1CC(=O)N(c2ccc(OCc3cccc(F)c3)cc2)C1- Mol. weight
- 342.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707394 ↗
Also known as
- evt 302
- evt 302
- evt 302
- rg1577
- ro4602522
- ro4602522
- ro4602522
- sembragiline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02104648 | Phase 1 | Apr 1, 2014 | Roche |
| NCT01677754 | Phase 2 | Oct 24, 2012 | Roche |
| NCT01701089 | Phase 1 | Sep 1, 2012 | Roche |
| NCT01625806 | Phase 1 | Jul 1, 2012 | Roche |
| NCT01631422 | Phase 1 | Jun 1, 2012 | Roche |
| NCT00738595 | Phase 2 | Aug 1, 2008 | Evotec, Nuventra Pharma Sciences, Inc., Pharmaceutical Research Associates, Inc. (PRA) |
| NCT00622752 | Phase 2 | Feb 1, 2008 | Evotec, Parexel |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 2 | 2012 |
| Evotec | For profit | 2 | 2 | 1 | 2008 |
| Nuventra Pharma Sciences, Inc. | For profit | 1 | 0 | 1 | 2008 |
| Parexel | For profit | 1 | 0 | 1 | 2008 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1